- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00473733
Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 (GLP)
Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth.
We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients.
Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying.
Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Efrat Broide, MD
- Phone Number: 972-8-9779722
- Email: efibroide@yahoo.com
Study Locations
-
-
-
Zerifin, Israel, 70300
- Assaf Harofeh Medical Center
-
Contact:
- Efrat Broide, MD
- Phone Number: 972-8-9779722
- Email: efibroide@yahoo.com
-
Principal Investigator:
- Efrat Broide, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years
Exclusion Criteria:
- Patients with neurological disease will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Efrat Broide, MD, Ethic committee of Asaaf Harofeh Medical Center
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 65/07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on GLP receptors expression
-
Medical College of WisconsinRecruitingChronic Lung DiseaseUnited States
-
Ricardo Pereira MestreInstitute of Oncology Research (IOR); Istituto Cantonale di PatologiaCompleted
-
AdaptimmuneTerminatedSolid and Hematological MalignanciesUnited States, Canada
-
Kafrelsheikh UniversityFoshan University Laboratory of Emerging Infectious Disease Institute of...Not yet recruiting
-
Zealand PharmaProfil Institut für Stoffwechselforschung GmbHRecruitingSafety and TolerabilityGermany
-
Dompé Farmaceutici S.p.AActive, not recruitingNew-onset type1 DiabetesUnited States, Belgium, Georgia, Germany, Italy, Serbia, Israel, Slovenia
-
Zealand PharmaCompleted
-
Zealand PharmaCompleted
-
University of PadovaAzienda Ospedaliera di PadovaUnknown
-
TC Erciyes UniversityCompletedHealthy | Autism Spectrum Disorder | High-functioning Autism